ALXO - ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting | Benzinga
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting, which will be held in San Diego from April 5-10, 2024.
Session titles and information for the two abstracts are listed below and are now available on the AACR online program planner.
A Phase 1 investigator-initiated trial of ...